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Background: For outpatients with pneumonia, guidelines recommend empiric antibiotics and
some suggest macrolides are preferred agents. We hypothesized that both guideline-
concordant antibiotics and macrolides would be associated with reduced mortality.
Methods: All outpatients with pneumonia assessed at 7 Emergency Departments in Edmonton,
Alberta, Canada were enrolled in a population-based registry that included clinical-
radiographic data, Pneumonia Severity Index (PSI) and treatments. Guideline-concordant regi-
mens included macrolides and respiratory fluoroquinolones; other regimens were “discor-
dant”. Main outcome was 30-day all-cause mortality.
Results: The study included 2973 outpatients; mean age 51 years, 47% female, most had mild
pneumonia (73% PSI Class IeII). Over 30-days, 38 (1%) patients died, 228 (8%) were hospital-
ized, and 253 (9%) reached the endpoint of death or hospitalization. Most (2845 [96%]) patients
received guideline-concordant antibiotics. Compared to patients receiving discordant antibi-
otics, those receiving guideline-concordant antibiotics were less likely to die within 30-days
(8 [6%] versus 30 [1%], adjusted OR 0.23, 95% CI 0.09e0.59, p Z 0.002). Within the
guideline-concordant subgroup, compared to the 947 (33%) patients treated with fluoroquino-
lones, those receiving macrolides [1847 (64%)] were less likely to die (25 [3%] versus 4 [0.2%],
adjusted OR 0.28, 95% CI 0.09e0.86, p Z 0.03).
Conclusions: In outpatients with pneumonia, treatment with guideline-concordant antibiotics
and macrolides were both associated with mortality reduction.
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452 L. Asadi et al.Community acquired pneumonia (CAP), combined with hospitalized within the previous 10e14 days, were preg-
influenza, is the eighth leading cause of death in developed
nations.1,2 In 2006, in the US alone, there were 4.2 million
ambulatory care visits for pneumonia with direct costs of
almost $9 billion annually.2e4 Although 80% of the treatment
for CAP is provided in the outpatient setting,5,6 most of the
published research has only studied hospitalized patients.
The most commonly identified bacterial etiologies for
pneumonia in theoutpatient setting are similar to inpatients,
and include “typical” organisms such as Streptococcus
pneumoniae and Haemophilus influenzae and “atypical”
organisms such as Mycoplasma pneumoniae, Chlamydophila
pneumoniae, and Legionella spp.7 Unfortunately, available
diagnostic studies only identify the causative organism in
about half of cases.7 Therefore, empiric treatment is needed
and most treatment guidelines acknowledge this premise.8
The recommended treatment regimens are based upon the
likely etiologic agents, expected susceptibilities, and expert
opinion. Recent studies of hospitalized patients with pneu-
monia report that use of guideline-concordant antibiotics
reduce morbidity and mortality.9e12 In addition, several
recent lines of evidence indicate that regimens containing
macrolides lead to improved outcomes.13e17
Therefore, we undertook a population-based cohort
study of more than 3000 outpatients with pneumonia. We
hypothesized that guideline-concordant antibiotics in
general, and macrolide antibiotics in particular, would be
associated with reduced 30-day all-cause mortality in
outpatients with pneumonia.
Methods
Subjects and setting
We conducted a population-based prospective cohort study
of all adult outpatients with community acquired pneu-
monia (CAP) seen at seven Emergency Departments (EDs) in
Edmonton, Alberta, Canada. Patients were enrolled from
2000 to 2002 and followed until 2007. The sites included
two tertiary care hospitals, two hospitals that provided
secondary and tertiary care, two community hospitals and
one free-standing ED.
CAP was defined as two or more symptoms or signs
(cough, productive or nonproductive; pleuritic chest pain;
shortness of breath; temperature > 38 C; and crackles, or
bronchial breathing on auscultation) plus radiographic
evidence of pneumonia as interpreted by the treating
physician. All CAP patients in the cohort were managed
according to a validated clinical pathway that outlined
recommendations for triage (based on the Pneumonia
Severity Index [PSI]), investigations and guideline-
concordant antibiotics. Any patient with a PSI score >90
(Class IV or V) or any patient that the ED physician thought
required hospital admission was referred to an inpatient
physician. All others were treated as outpatients and dis-
charged home. Excluded from the pathway (and thus, our
study) were immunosuppressed patients, defined as
patients who were using 10 mg per day of prednisone for 1
month,or who were using other immunosuppressive agents,
or who had human immunodeficiency virus with a CD4 cell
count < 250/mL.As well, excluded were those who had beennant, or had tuberculosis or cystic fibrosis. The study was
approved by the Health Ethics Review Board of the
University of Alberta (Edmonton, Alberta, Canada; approval
#Pro00004999).
Data collected
Trained research nurses collected sociodemographic vari-
ables, clinical characteristics (e.g., premorbid functional
status, smoking status), laboratory tests and chest radio-
graph reports for all patients. The PSI was calculated at point
of care as part of the pathway. The PSI is a summarymeasure
of the severity of pneumonia-specific illness at presentation
and it is based on three demographic variables (age, sex,
nursing home residence), five co-morbidities (cancer,
chronic kidney disease [CKD], heart failure, liver disease,
stroke), five physical findings (confusion, tachypnea,
tachycardia, hypotension, fever or hypothermia), and seven
laboratory tests (acidosis, elevated BUN, hyponatremia,
hyperglycemia, anemia; hypoxemia, pleural effusion on
chest radiograph). The PSI score (continuous variable) is an
exhaustively validated summary measure of 20 independent
prognostic variables for patients with pneumonia and it is
designed to predict 30-day all-cause mortality.
Antibiotic regimens
Pre-printed prescriptions with suggested antibiotic options
were provided to all ED physicians as part of the clinical
pathway, although there were no mandatory choices. The
antibiotics recommended were 10-days of any one of the
following: doxycycline 200 mg po  1 then 100 mg po BID,
levofloxacin 500 mg po daily, azithromycin 500 mg po  1
then 250 mg po daily, clarithromycin 500 mg po BID or
erythromycin 500 mg po QID. For the purposes of our study,
a regimen needed to contain at least one of the antibiotics
on the pre-printed prescription to be considered “guide-
line-concordant”. The guideline-concordant antibiotic
choices were based on the 2000 IDSA CAP guidelines18 and
closely correspond with 2003 and 2007 guidelines (all
emphasizing coverage of “atypical” organisms such as C.
pneumoniae, M. pneumoniae and Legionella spp).8,19
Within the concordant antibiotic choices, we examined
differences between the macrolides and the respiratory
fluoroquinolones. Any regimen that did not have doxycy-
cline, a respiratory fluoroquinolone, or a macrolide was
considered “guideline-discordant”. Because “over-treat-
ment” might be considered guideline-discordant by some,
we undertook a sensitivity analysis wherein we excluded
the 16 patients that received non-recommended combina-
tion regimens irrespective of whether or not atypical
coverage was provided.
Outcomes
The primary outcome was 30-day all-cause mortality. In
addition, we examined the composite endpoint of 30-day
mortality or hospitalization. These outcomes were ascer-
tained using multiple linked and well-validated provincial
administrative databases.20 The rate of successful linkage
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provincial administrative databases generally exceeds 95%.20Statistical analysis
The baseline characteristics of patients receiving guideline-
concordant versus discordant antibiotics were compared
using a c2 or Students’ t-test, as appropriate. Multivariable
logistic regression was used to determine the independent
association between receipt of guideline-concordant anti-
biotics and 30-day mortality. We forced use of guideline-
concordant antibiotics (dichotomous variable representing
the independent exposure of interest), the PSI (continuous
summary measure of pneumonia severity calculated using
20 variables: age, sex, nursing home status, 5 co-morbid-
ities, 5 physical signs, and 7 laboratory findings) and chest
radiograph confirmation of pneumonia into all models. We
did not separately adjust for older age, sex, and nursing
home residence again because the PSI already controls for
these variables and because we wanted to avoid unneces-
sary overfitting of models; with only 38 “events” we could
only adjust for 3e4 variables before overfitting might arise.
We refer to our final models as “age, sex, and clinical-
radiographic severity of illness at presentation” adjusted.
We then considered other variables based on clinical
importance, univariate p-values < 0.1 or when a variable
confounded (a confounder was identified by a greater than
10% change in beta-coefficient) the association between
use of guideline-concordant antibiotics and outcomes,
irrespective of statistical significance. We tested all first
order interaction terms, but none achieved statistical
significance and none were included. As a measure ofTable 1 Characteristics of 2973 outpatients with pneumonia ac
Characteristics Guideline-concordan
antibiotics, n Z 2845
No. (%)
Age in years, Mean (SD) 51.4 (20.0)
Age > 65 804 (28)
Female 1132 (47)
Nursing home resident 116 (4)
Current Smoker 570 (20)
Impaired Mobility 140 (5)
Co-morbidities
Cancer 149 (5)
COPD 235 (8)
Heart Failure 104 (4)
Diabetes Mellitus 199 (7)
Liver Disease 25 (1)
Chronic Kidney Disease 58 (2)
Pneumonia Severity Index
Mean (SD) Score 54.5 (28.5)
Class I 448 (16)
Class II 1654 (58)
Class III 408 (14)
Class IV 290 (10)
Class V 45 (2)
Chest Radiograph Confirmed
Pneumonia
1512 (53)model “fit” we calculated the c-statistics (akin to the ROC
or area under the curve).
We then restricted analyses to only those patients who
had received guideline-concordant antibiotics. We
excluded doxycycline users as well as those who had
received any combination therapy, as these regimens made
up less than 3% of the guideline-concordant antibiotic
regimens. We compared respiratory fluoroquinolone with
macrolide monotherapy and undertook identical analyses
to those already described to determine the independent
association between macrolide monotherapy and
outcomes.
We carried out 12 sensitivity analyses, 6 for the guide-
line concordance studies and then repeated the same 6
analyses for the macrolide versus quinolone studies. First,
we used an alternate approach to control for pneumonia
severity. Rather than use the PSI score, we created models
that directly adjusted for age, sex, nursing home status, all
17 of the other variables included in the PSI, chest radio-
graph confirmation and then included guideline-concordant
antibiotic use.
Second, using standard methods,23 we conducted
a propensity (to receive guideline-concordant antibiotics or
macrolides) score adjusted analysis of outcomes rather
than the traditional multivariable logistic regression models
used for our main analyses. The propensity score is inten-
ded to control for the possibility of physician selection bias
(i.e., forms of confounding by indication or channeling) and
other unmeasured confounders.23 The variables included in
the propensity score were all variables presented in Table 1
as well as number of medications, site of care, and a term
for age-squared that helped improve model fit as assessed
by the c-statistic.23cording to the use of guideline-concordant antibiotics.
t Guideline-discordant
antibiotics, n Z 128
No. (%)
P value
52.5 (22.0) 0.54
46 (36) 0.06
61 (48) 0.85
14 (11) <0.001
18 (14) 0.10
17 (13) <0.001
10 (8) 0.20
16 (13) 0.10
7 (5) 0.29
12 (9) 0.30
2 (2) 0.43
8 (6) 0.002
63.1 (35.3) 0.001
13 (10) 0.002
61 (48)
29 (23)
21 (16)
4 (3)
71 (55) 0.61
Table 2 The number and proportion of guideline-
concordant versus discordant antimicrobial regimens used
for outpatients with pneumonia.
Antimicrobial Regimens Patients, No. (%)
Guideline-Concordant (n Z 2845)
Macrolides 1832 (64)
Azithromycin 1292 (45)
Clarithromycin 518 (18)
Erythromycin 22 (1)
Quinolones 947 (33)
Levofloxacin 915 (32)
Moxifloxacin 28 (1)
Gatifloxacin 4 (0.1)
Doxycycline 26 (1)
Macrolide þ Beta-lactam 24 (1)
Other Combinations 16 (1)
Guideline-Discordant (n Z 128)
Cephalosporins 55 (43)
Amoxicillin or Amoxicillin-Clavulanate 35 (27)
Ciprofloxacin 13 (10)
Trimethoprim-Sulfamethoxazole 8 (6)
Other Combinations 17 (13)
454 L. Asadi et al.Third, we re-ran the main analyses after excluding 1390
patients with chest radiographs interpreted as normal by
radiologists post-discharge, as some experts still contend
that one cannot have pneumonia without radiographic
abnormalities on plain films.21,22 Fourth, we re-ran analyses
after excluding 725 patients at high risk of multi-drug
resistant (MDR) organisms because of nursing home resi-
dence, impaired functional status, or already treated with
antibiotics before presentation. As mentioned, patients
recently discharged from hospital were already excluded.
Fifth, we removed 16 patients who were over-treated from
guideline-concordant group and re-ran analyses.
Last, we re-examined outcomes among all 2779 patients
that survived to 30-days and followed them until 1-year after
their episode of pneumonia (i.e., a post-convalescent anal-
ysis). Because it is somewhat implausible that short-term
exposure to guideline-concordant antibiotics would affect
outcomes so longafter theacuteepisodeof illness haspassed,
a statistically significant benefit attributable to antibiotic
exposure still present at 1-year would suggest residual and
possibly refractory confounding. All analyses were conducted
using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA.)
Results
Patient characteristics
Overall, almost 7000 consecutive adult patients were tri-
aged and treated according to the validated clinical pathway
for pneumonia. Of these patients, 3344 were discharged
home from the ED and potentially eligible for inclusion. We
excluded 237 (8%) patients who could not be linked to
provincial administrative databases and 134 (3%) patients
without any antibiotic data, leaving a final sample size of
2973 outpatients. The mean age was 51 (SD 20) years, 47%
were female, and 73% had “mild” pneumonia (PSI Class IeII;
see Table 1). Only 16 (<1%) patients left the ED against
medical advice. Within 30-days, 38 (1%) patients had died,
228 (8%) were admitted to hospital, and 253 (9%) reached the
composite endpoint of death or hospitalization.
Site-level clinical pathway adherence
In terms of overall measures of adherence to the clinical
pathway, 100% of patients had a chest radiograph, 96%
received guideline-concordant antibiotics, 94% had oxygen
saturation measured and 88% of those discharged home had
PSI Class IeIII pneumonia. Overall use of guideline-
concordant antibiotics across the seven sites was very
high (96%). There was minimal variation across the sites,
with rates of guideline-concordant antibiotic use ranging
from 94 to 98% (p Z 0.11).
Guideline-concordant versus discordant antibiotic
use
Most (n Z 2845, 96%) patients received guideline-
concordant antibiotics. Only 16 (<1%) of these patients
might be considered to have received “discordant” regi-
mens on the basis of over-treatment with non-recommended combination regimens (Table 1). Those who
received guideline-concordant antibiotics were younger,
less likely to be from a nursing home or have impaired
mobility, and had less severe pneumonia (Table 1). Overall,
respiratory fluoroquinolones (nZ 947, 34%) and macrolides
(n Z 1832, 66%) were the most commonly used regimens
(Table 2). Patients receiving guideline-concordant therapy
were less likely to die within 30-days (8[6%) v. 30[1%] with
discordant antibiotics, p < 0.001 for difference, see Fig. 1).
The independent association between receipt of guideline-
concordant antibiotics and mortality persisted in multivar-
iable analyses that controlled for age, sex, and clinical-
radiographic severity of illness at presentation (adjusted
OR 0.23; 95%; CI 0.09e0.59; pZ 0.002; c-statisticZ 0.90).
There was also a non-significant reduction in the combined
endpoint of 30-day death or hospitalization with guideline-
concordant antibiotic use (20 [16%] versus 233 [8%]), age,
sex, and clinical-radiographic severity of illness at presen-
tation adjusted OR 0.64; 95% CI 0.37e1.09; p Z 0.10; c-
statistic Z 0.76 and see Fig. 1).
In terms of sensitivity analyses, regardless of how
severity of pneumonia was modeled, use of propensity
scores (c-statistic for propensity model Z 0.70), or exclu-
sion of 3 pre-defined subgroups of patients, the main results
of our analyses with respect to 30-day all-cause mortality
were essentially unaltered although some results achieved
only borderline statistical significance (Fig. 2). Conversely,
in the post-convalescent analysis among 2935 30-day
survivors, guideline-concordant antibiotics were not asso-
ciated with reduced 1-year mortality (adjusted OR 0.75,
95% CI 0.37e1.54, p Z 0.43).
Macrolide versus respiratory fluoroquinolone use
Within the guideline-concordant subgroup of 2845 patients,
there were 1832 (66%) macrolide users and 947 (33%)
respiratory fluoroquinolone users. Their characteristics,
Figure 1 30-Day outcomes for outpatients with pneumonia
who received guideline-concordant (either macrolide or
respiratory fluoroquinolone based) versus guideline-discordant
antibiotic regimens.
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Compared to fluoroquinolone users, the patients treated
with macrolides were younger, healthier, and had less
severe pneumonia (Table 3). In terms of 30-day mortality, 4
of 1832 (0.2%) macrolide users died versus 25 of 947 (3%)
fluoroquinolone users (age, sex, and clinical-radiographic
severity of illness adjusted OR 0.28; 95% CI 0.09e0.86;
p Z 0.030; c-statistic Z 0.89 and see Fig. 1). There was
also a statistically significant reduction for the composite
endpoint of death or hospitalization within 30-days: 90 (5%)
with macrolides versus 137 (14%) for fluoroquinolones (age,
sex, and clinical-radiographic severity of illness adjusted
OR 0.61; 95% CI 0.45e0.84; p Z 0.003; c-statistic Z 0.80).
In terms of sensitivity analyses, regardless of how
severity of pneumonia was modeled, use of propensity
scores (c-statistic for modelZ 0.78), or exclusion of 2 pre-
defined subgroups of patients, the main results of our
analyses with respect to 30-day all-cause mortality were
similar (Fig. 3). Conversely, in the final post-convalescent
analysis among the 2749 30-day survivors who had been
exposed to guideline-concordant antibiotics, macrolide use
itself was not associated with reduced 1-year mortality
(adjusted OR 0.70, 95% CI 0.47e1.04, p-value Z 0.08).Figure 2 Six sensitivity analyses with respect to guideline-
concordant antibiotic treatments and 30-day mortality.Discussion
In a population-based cohort of almost 3000 outpatients
with pneumonia managed according to a validated clinical
pathway, we found high rates (96%) of guideline-concordant
antibiotic treatment could be achieved with little variation
across 7 sites. Furthermore, guideline-concordant antibi-
otic use was associated with a significant 77% adjusted
relative reduction in 30-day all-cause mortality. Within the
guideline-concordant subgroup, we also found that those
who used macrolides had a 72% adjusted relative reduction
in 30-day mortality when compared to those treated with
fluoroquinolones.
To our knowledge, this is the largest prospective study
investigating the impact of guideline-concordant antibiotic
use in outpatients with pneumonia, as well as the first to
report a clinical benefit with either guideline concordance
or macrolide use. Previous studies in outpatients with
pneumonia were either relatively small, retrospective, or
had limited clinical data for multivariable adjust-
ment.5,24,25 Gleason et al. prospectively looked at 864
outpatients and found that antibiotic treatments concor-
dant with the 1993 ATS guidelines did not improve
outcomes, perhaps because these guidelines did not
recommend routine coverage for atypical organisms.24
In contrast to outpatient studies, the mortality benefits
we observed with guideline-concordant antibiotic use are
similar to the results of several studies in hospitalized
patients with more severe pneumonia.9e12 These investi-
gators have usually interpreted their findings as evidence
that atypical coverage leads to better outcomes.9,12 Given
that at least 20e30% of patients with pneumonia have
infections with atypical organisms, perhaps this is
unsurprising.7,26
More surprising, perhaps, is that the patients exposed to
macrolides had significantly lower 30-day mortality than
those exposed to respiratory fluoroquinolones. While this
phenomenon has been consistently documented with
observational studies of hospitalized patients,15e17 it has
not previously been reported for outpatients. Furthermore,
in a systematic review of six active-comparator randomized
trials of antibiotic treatment in 1857 very low risk outpa-
tients with pneumonia, macrolide related mortality bene-
fits were not demonstrable.27 However, there were no
reported deaths in these six trials compared with the 38
deaths in our cohort of 2973 patients. Our study is larger
than all the published trials together and it might simply be
that the trial subjects studied were at such low risk of
mortality that a benefit could not be appreciated.
If our results are not a result of chance, bias, or con-
founding, the most likely mechanistic explanation rests on
the macrolide-specific immunomodulatory effects that
have been previously reported.28 These effects are
believed to be mediated by several properties of macro-
lides that have been observed, in-vitro and in-vivo, and
include: decreases in pro-inflammatory cytokines (TNF-a,
IL-1, IL-6, IL-8 and IFN-g), increases in anti-inflammatory
cytokines, and decreases in neutrophil chemotaxis, leuko-
cyte adhesion, and oxidative metabolism.29Although the
evidence is more limited, in fact the fluoroquinolones also
modulate the immune system and have been demonstrated
to reduce pro-inflammatory cytokine levels and inhibit
Table 3 Characteristics of 2779 outpatients with pneumonia who received guideline-concordant antibiotics stratified by
antibiotic treatment.
Characteristics Macrolide-Based
Regimens n Z 1832,
No. (%)
Respiratory Fluoroquinolones
n Z 947, No. (%)
P Value
Age in years, Mean (SD) 46.1 (17.9) 61.9 (19.7) <0.001
Age > 65 314 (17) 470 (50) <0.001
Female 871 (48) 427 (45) 0.22
Nursing home resident 17 (1) 97 (10) <0.001
Current Smoker 151 (16) 405 (22) <0.001
Impaired Mobility 34 (2) 101 (11) <0.001
Co-morbidities
Cancer 55 (3) 90 (10) <0.001
COPD 58 (3) 171 (18) <0.001
Heart Failure 23 (1) 78 (8) <0.001
Diabetes Mellitus 83 (5) 112 (12) <0.001
Liver Disease 17 (1) 8 (1) 0.83
Chronic Kidney Disease 18 (1) 39 (4) <0.001
Pneumonia Severity
Mean (SD) Score 46.0 (22.6) 71.3 (31.4) <0.001
Class I 363 (20) 78 (8) <0.001
Class II 1209 (66) 404 (43)
Class III 181 (10) 217 (23)
Class IV 76 (4) 207 (22)
Class V 3 (0.2) 41 (4)
Chest Radiograph Confirmed
Pneumonia
528 (56) 948 (52) 0.04
456 L. Asadi et al.secretion of TNF-a, IL-6 and IL-8.30 Although we cannot
examine the degree and balance of immunodulation that
might be present, it might be interesting to speculate that
the non-microbial effects of both antibiotic classes are
among the reasons that the guideline-concordant patients
(99% exposed to macrolide or fluoroquinolone) had such
good outcomes.28e30
Despite the strengths of this study, we acknowledge at
least five limitations. First, it was not a randomized trial and
“confounding by indication” could explain our results. This is
of course the major limitation of any observation study and
not restricted to our work. Second, we do not know why
treating physicians chose a particular antibiotic regimen orFigure 3 Five sensitivity analyses with respect to macrolide
antibiotic treatment and 30-day mortality.elected to be guideline-discordant. Third, we also do not
know (other than for those few discharged against medical
advice) why certain groups of patients were discharged
home when guidelines suggested hospital admission. For
example, 360 (12%) of our study patients had severe or very
severe pneumonia (PSI Class IV or V) and were still treated as
outpatients. Some of this could relate to very clinically well-
looking older patients as the PSI is driven heavily by age, but
it is also possible this is the reason our mortality and re-
admission rates might seem high. Fourth, we did not have
any post-discharge microbiologic data and do not know the
proportion of patients who may have had an atypical
bacterial infection or macrolide-resistant S. pneumoniae.
Fifth, somemight be concerned about the generalizability of
our findings given the cohort was enrolled between 2000 and
2002 and our definitions of guideline-concordant treatments
were based on older guidelines.
In conclusion, in a large prospective population-based
study of outpatients with pneumonia, receipt of guideline-
concordant antibiotics was associated with a significant 77%
reduction in 30-day mortality while those treated with mac-
rolides had the lowest mortality of all. Consistent with work
done in hospitalized patients9e12 our study suggests that
treatment with guideline-concordant antibiotics that cover
atypical infections and macrolide-based regimens are asso-
ciatedwith better outcomes for outpatientswithpneumonia.Acknowledgments
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